Syndax Pharmaceuticals (SNDX) News Today $16.38 +0.39 (+2.44%) Closing price 04:00 PM EasternExtended Trading$16.32 -0.05 (-0.34%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.7% - Here's What HappenedSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 6.7% - Here's What HappenedFebruary 21 at 3:18 PM | marketbeat.comHere's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn SituationFebruary 20 at 11:43 AM | finance.yahoo.comAnalysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $36.20February 19 at 1:32 AM | americanbankingnews.comSyndax Pharmaceuticals (SNDX) Expected to Announce Earnings on TuesdaySyndax Pharmaceuticals (NASDAQ:SNDX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 5:35 AM | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmFebruary 17, 2025 | investing.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine havFebruary 16, 2025 | marketbeat.comSyndax Pharmaceuticals CEO sells $206,017 in sharesFebruary 13, 2025 | msn.comKeith A. Goldan Sells 3,777 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) StockFebruary 13, 2025 | insidertrades.comSyndax pharmaceuticals CFO Keith Goldan sells $58,558 in stockFebruary 12, 2025 | msn.comSyndax pharmaceuticals CFO sells $58,558 in stockFebruary 12, 2025 | msn.comInsider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith A. Goldan sold 3,777 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares of the company's stock, valued at approximately $1,406,563. This represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.February 12, 2025 | marketbeat.comNeil Gallagher Sells 4,618 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 12, 2025 | marketbeat.comInsider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells 13,288 Shares of StockSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at $4,651,875.50. This represents a 4.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 12, 2025 | marketbeat.com2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall StreetFebruary 11, 2025 | msn.comabrdn plc Purchases Shares of 99,340 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)abrdn plc purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 99,340 shares of the company's stock, valued at approximately $1,313,000. abrdn plc owned 0.12% of SynFebruary 11, 2025 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmFebruary 10, 2025 | globenewswire.comKura Oncology falls despite trial success; rival Syndax gainsFebruary 6, 2025 | seekingalpha.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up - Here's What HappenedSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up - Time to Buy?February 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 4, 2025 | prnewswire.comSyndax Announces Participation in February Investor ConferencesJanuary 30, 2025 | prnewswire.comPromising 2025 Outlook for Syndax Pharmaceuticals: Strategic Product Launches and Expansion Plans Drive Buy RecommendationJanuary 24, 2025 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Moderate Buy" by AnalystsSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have assJanuary 22, 2025 | marketbeat.comSyndax Looks Tantalizing, But Looks Can Be DeceptiveJanuary 22, 2025 | seekingalpha.comAssenagon Asset Management S.A. Buys 1,598,428 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Assenagon Asset Management S.A. raised its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 343.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,064,456 shares of the company's stockJanuary 17, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest UpdateSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 21,310,000 shares, an increase of 30.3% from the December 15th total of 16,360,000 shares. Based on an average daily trading volume, of 1,990,000 shares, the short-interest ratio is currently 10.7 days.January 16, 2025 | marketbeat.comIncyte And Syndax : FDA Approves Niktimvo 9 Mg And 22 Mg Vial SizesJanuary 16, 2025 | markets.businessinsider.comIncyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vialsJanuary 16, 2025 | msn.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America SecuritiesJanuary 16, 2025 | markets.businessinsider.comIncyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial SizesJanuary 15, 2025 | prnewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week Low - What's Next?Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year Low - Time to Sell?January 14, 2025 | marketbeat.comSyndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | prnewswire.comInvesting in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gainJanuary 10, 2025 | finance.yahoo.comSyndax price target lowered to $16 from $18 at ScotiabankJanuary 9, 2025 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)January 9, 2025 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at ScotiabankScotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Wednesday.January 8, 2025 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmJanuary 7, 2025 | prnewswire.comSyndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | prnewswire.comBank of America Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)January 7, 2025 | markets.businessinsider.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 3, 2025 | prnewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1% - Here's What HappenedSyndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.1% Higher - Here's WhyDecember 31, 2024 | marketbeat.comKuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law FirmDecember 29, 2024 | markets.businessinsider.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buyDecember 28, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year Low - What's Next?Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week Low - Should You Sell?December 26, 2024 | marketbeat.comGeode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Geode Capital Management LLC grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,977,082 shares of the company's stock after purchasinDecember 25, 2024 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6% - Here's WhySyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 2.6% - What's Next?December 24, 2024 | marketbeat.comBarclays PLC Raises Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Barclays PLC raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 143.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 187,629 shares of the company's stock after purchasing an additional 110,535 sDecember 23, 2024 | marketbeat.comSyndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvalsDecember 22, 2024 | uk.investing.comBarclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)December 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of DirectorsDecember 19, 2024 | prnewswire.comFranklin Resources Inc. Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)Franklin Resources Inc. grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 13.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,763,277 shares of the compDecember 19, 2024 | marketbeat.com Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Media Mentions By Week SNDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNDX News Sentiment▼0.510.60▲Average Medical News Sentiment SNDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNDX Articles This Week▼65▲SNDX Articles Average Week Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GRFS News TGTX News KRYS News SWTX News BHVN News RXRX News PTCT News OGN News RARE News ALVO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNDX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts